Bovine papillomavirus type 4: Neoplastic cell transformation and control of infection by vaccination (review)

International Journal of Oncology

Volumn 9, Issue 6, 1996, Pages 1189-1199

  Jackson, Maria E ^a,b   O'Brien, Vincent ^a   Morgan, Iain M ^a   Grindlay, G Joan ^a   Campo, M Saveria ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

bovine papillomavirus type 4; neoplastic transformation; vaccination

Indexed keywords

VIRUS VACCINE;

ARTICLE; INTESTINE CANCER; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; VACCINATION; VIRUS CELL TRANSFORMATION; VIRUS INFECTION; VIRUS ONCOGENE;

EID: 0029834732     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (126)

1. zur Hausen H: Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. In: Human Pathogenic Papillomaviruses, Current Topics in Microbiology and Immunology, vol 186, pp131-156, 1994.
2. Pfister H, Gassenmaier A, Nurnberger F and Stuttgen G: Human papillomavirus 5 DNA in carcinoma of an epidermodysplasia verruciformis patient infected with various human papillomavirus types. Cancer Res 43: 1436-1441, 1983.
3. Bunney MH, Barr BB, McLaren K, Smith IW, Benton EC, Anderton JL and Hunter JAA: Human papillomavirus type 5 and skin cancer in renal allograft recipients. Lancet ii: 151-152, 1987.
4. Watts SL, Brewer EE and Fry TL: Human papillomavirus DNA types in squamous carcinomas of the head and neck. Oral Surg Oral Med Oral Pathol 71: 701-707, 1991.
5. Jarrett WFH, Campo MS, O'Neil BW, Laird HM and Coggins LW: A novel bovine papillomavirus (BPV6) causing true epithelial papillomas of the mammary gland skin: a member of a proposed new BPV subgroup. Virology 136: 255-264, 1984.
6. Campo MS, Jarrett WFH, Barron R, O'Neil BW and Smith KT: Association of bovine papillomavirus type 2 and bracken fern with bladder cancer in cattle. Cancer Res 52: 6898-6904, 1992.
7. Campo MS, O'Neil BW, Barron RJ and Jarrett WFH: Experimental reproduction of the papilloma-carcinoma complex of the alimentary canal in cattle. Carcinogenesis 15: 1597-1601, 1994.
8. Evans IA, Prorok JH, Cole RC, Al-Samani MH, Al-Samarrai AM, Patel MC and Smith RMN: The carcinogenic, mutagenic and teratogenic toxicity of bracken. Proc Royal Soc Edinburgh 81: 65-77, 1982.
9. Evans WC, Patel MC and Koohy Y: Acute bracken poisoning in homogastric and ruminant animals. Proc Royal Soc Edinburgh 81: 29-64, 1982.
10. Jarrett WFH, McNeil PE, Grimshaw WTR, Selman IE and McIntyre WIM: High incidence area of cattle cancer with a possible interaction between an environmental carcinogen and a papilloma virus. Nature 274: 215-217, 1978.
11. Plowright W, Linsell CA and Peers FG: A focus of rumenal cancer in Kenyan cattle. Br J Cancer 25: 72-80, 1971.
12. Moura JW, Stocco dos Santos RC, Dagli MLZ, D'Angelino JL, Birgel EH and Becak W: Chromosome aberrations in cattle raised on bracken fern pasture. Experientia 44: 785-788, 1988.
13. Campo MS, Moar MH, Sartirana ML, Kennedy IM and Jarrett WFH: The presence of bovine papillomavirus type 4 DNA is not required for the progression to, or maintenance of, the malignant state in cancers of the alimentary canal in cattle. EMBO J 4: 1819-1825, 1985.
14. Gaukroger JM, Chandrachud L, Jarrett WFH, McGarvie GE, Yeudall WA, McCaffery RE, Smith KT and Campo MS: Malignant transformation of a papilloma induced by BPV4 in the nude mouse renal capsule. J Gen Virol 72: 1165-1168, 1991.
15. Jarrett WFH: The natural history of bovine papillomavirus infections. Adv Viral Oncol 5: 83-102, 1985.
16. Roden RBS, Kimbauer R, Jenson AB, Lowy DR and Schiller JT: Interaction of papillomaviruses with the cell surface. J Virol 68: 7260-7266, 1994.
17. Lambert PF: Papillomavirus DNA replication. J Virol 65: 3417-3420, 1991.
18. Yang L, Li R, Mohr IJ, Clark R and Botchan MR: Activation of BPV1 replication in vitro by the transcription factor E2. Nature 353: 628-632, 1991.
19. Hirochika H, Broker TR and Chow LT: Enhancers and transacting E2 transcriptional factors of papillomaviruses. J Virol 61: 2599-2606, 1987.
20. Lambert PF, Spalholz BA and Howley PM: A transcriptional repressor encoded by BPV1 shares a common C-terminus with the E2 transactivator. Cell 50: 69-78, 1987.
21. Bernard BA, Bailly C, Lenoir MC, Darmon M, Thierry F and Yaniv M: The human papillomavirus type 18 (HPV18) E2 gene product is a represser of the HPV18 regulatory region in human keratinocytes. J Virol 63: 4317-4324, 1989.
22. Stenlund A and Botchan MR: The E2 transactivator can act as a repressor by interfering with a cellular transcription factor. Genes Dev 4: 123-136, 1990.
23. Campo MS: Cell transformation by animal papillomaviruses. J Gen Virol 73: 217-222, 1992.
24. Jackson ME, Pennic WD, McCaffery RE, Smith KT, Grindlay GJ and Campo MS: The B subgroup bovine papillomaviruses lack an identifiable E6 open reading frame. Mol Carcinogen 4: 382-387, 1991.
25. Stamps AC and Campo MS: Mapping of two novel transcripts of bovine papillomavirus type 4. J Gen Virol 68: 3033-3045, 1988.
26. Jackson ME and Campo MS: Both viral E2 protein and the cellular factor PEBP2 regulate transcription via E2 consensus sites within the bovine papillomavirus type 4 long control region. J Virol 69: 6038-6046, 1995.
27. Smith KT, Patel KR and Campo MS: Transcriptional organisation of bovine papillomavirus type 4. J Gen Virol 67: 2381-2393, 1986.
28. Doorbar J, Evans HS, Coneron I, Crawford LV and Gallimore PH: Analysis of HPV1 E4 gene expression using epitope-defined antibodies. EMBO J 7: 825-833, 1988.
29. Favre M, Breitburd F, Croissant O and Orth G: Structural polypeptides of rabbit, bovine and human papillomaviruses. J Virol 15: 1239-1247, 1975.
30. Lees E, Osborn K, Banks L and Crawford L: Transformation of primary BRK cells by human papillomavirus type 16 and EJ-ras is increased by overexpression of the viral E2 protein. J Gen Virol 71: 183-193, 1990.
31. Jaggar RT, Pennie WD, Smith KT, Jackson ME and Campo MS: Cooperation between bovine papillomavirus type 4 and ras in the morphological transformation of primary bovine fibroblasts. J Gen Virol 71: 3041-3046, 1990.
32. Smits HL, Raadsheer E, Rood I, Mehendale S, Slater RM, van der Noordaa and ter Schegget J: Induction of anchorage independent growth of human embryonic fibroblasts with a deletion in the short arm of chromosome 11 by human papillomavirus type 16 DNA. J Virol 62: 4538-4543, 1988.
33. Durst M, Kleinheinz A, Hotz M and Gissman L: The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumurs. J Gen Virol 66: 1515-1522, 1985.
34. Jackson ME and Campo MS: Positive and negative E2-independent regulatory elements in the long control region of bovine papillomavirus type 4. J Gen Virol 72: 877-883, 1991.
35. Gloss B and Bernard HLJ: The E6/E7 promoter of human papillomavirus type 16 is activated in the absence of E2 proteins by a sequence-aberrant Sp1 distal element. J Virol 64: 5577-5584, 1990.
36. Dostatni N, Lambert PF, Sousa R, Ham J, Howley PM and Yaniv M: The functional BPV1 E2 transactivating protein can act as a repressor by preventing formation of the initiation complex. Genes Dev 5: 1657-1671, 1991.
37. 105 promoters. J Virol 64: 2849-2859, 1990.
38. 105 promoter. New Biol 3: 90-100, 1991.
39. Piette J and Yaniv M: Two different factors bind to the α-domain of the polyomavirus enhancer, one of which also interacts with the SV40 and c-fos enhancers. EMBO J 6: 1331-1337, 1987.
40. Martin ME, Piette J, Yaniv M, Tang WJ and Folk WR: Activation of the polyomavirus enhancer by a murine activator protein 1 (AP1) homolog and two contiguous proteins. Proc Natl Acad Sci USA 85: 5839-5843, 1988.
41. Iftner T: Papillomavirus genomes: sequence analysis related to functional aspects. In: Papillomaviruses and Human Cancer. H. Pfister (Ed.), CRC Press Inc. Boca Raton, FL pp181-200, 1990.
42. Sibbet GJ, Cuthill S and Campo MS: The enhancer in the long control region of human papillomavirus type 16 is up-regulated by PEF-1 and down-regulated by Oct-1. J Virol 69: 4006-4011, 1995.
43. McCaffery RE and Jackson ME: An element binding a C/EBP-related transcription factor contributes to the negative regulation of the bovine papillomavirus type 4 long control region. J Gen Virol 75: 3047-3056, 1994.
44. Pei D and Shi C: Transcriptional activation and repression by cellular DNA binding protein C/EBP. J Virol 64: 1517-1522, 1990.
45. Smith KT and Campo MS: 'Hit and run' transformation of mouse C127 cells by bovine papillomavirus type 4: the viral DNA is required for the initiation but not for maintenance of the transformed phenotype. Virology 164: 39-47, 1988.
46. Pennie WD, Grindlay GJ, Cairney M and Campo MS: Analysis of the transforming functions of bovine papillomavirus type 4. Virology 193: 614-620, 1993.
47. Smith KT and Campo MS: Amplification of specific DNA sequences in C127 mouse cells transformed by bovine papillomavirus type 4. Oncogene 4: 409-413, 1989.
48. Smith KT, Coggins LW, Doherty I, Pennie WD, Cairney M and Campo MS: BPV4 induces amplification and activation of 'silent' BPV1 in a subline of C127 cells. Oncogene 8: 151-156, 1993.
49. Popescu NC and DiPaolo JA: Integration of human papillomavirus 16 DNA and genomic rearrangements in immortalised human keratinocyte lines. Cancer Res 50: 1316-1323, 1990.
50. Anderson RA, Scobie L, O'Neil BW, Grindlay GJ and Campo MS: Viral proteins of bovine papillomavirus type 4 during the development of alimentary canal tumours. Brit Vet J (In press).
51. Vousden KH, Doniger J, DiPaolo JA and Lowy DR: The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res 3: 167-175, 1988.
52. Barbosa MS, Lowy DR and Schiller JT: Papillomavirus peptides E6 and E7 are zinc binding proteins. J Virol 63: 1404-1407, 1989.
53. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E and Howley PM: Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumour supressor gene product. EMBO J 8: 4099-4105, 1989.
54. Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR and Vousden KH: The region of the HPV E7 oncoprotein homologous to adenovirus E1a and SV40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J 9: 153-160, 1990.
55. Storey A, Almond N, Osborn K and Crawford L: Mutations of the human papillomavirus type 16 E7 gene that affect transformation, transactivation and phosphorylation by the E7 protein. J Gen Virol 71: 965-970, 1990.
56. Massimi P, Pim D, Storey A and Banks L: HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Oncogene 12: 2325-2330, 1996.
57. Antinore MJ, Birrer MJ, Patel D, Nader L and McCance DJ: The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP-1 family of transcription factors. EMBO J 15: 1950-1960, 1996.
58. Zerfass K, Schulze Z, Spitkovsky D, Friedman V, Henglein B and Jansen-Durr P: Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J Virol 69: 6389-6399, 1995.
59. Iftner T, Sagner G, Pfister H and Wettstein FO: The E7 protein of human papillomavirus 8 is a nonphosphorylated protein of 17 kD and can be generated by two different mechanisms. Virology 179: 248-436, 1990.
60. Schlegel R and Wade-Glass M: E5 transforming polypeptide of bovine papillomavirus. In: Cancer Cells 5: Papillomaviruses. Steinberg BM, Brandsma JL, Taichman LB (Eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY pp87-91, 1987.
61. Martin P, Vass WC, Schiller JT, Lowy DR and Velu TJ: The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF ans CSF-1 receptors. Cell 59: 21-32, 1989.
62. Petti L, Nilson LA and DiMaio D: Activation of the platelet derived growth factor receptor by the bovine papillomavirus E5 transforming protein. EMBO J 4: 845-855, 1991.
63. Goldstein DJ and Schlegel R: The E5 oncoprotein of bovine papillomavirus binds to a 16 kD cellular protein. EMBO J 9: 137-146, 1990.
64. Holzenburg A, Jones PC, Franklin T, Pali T, Heimburg T, Marsh D, Findlay JBC and Finbow ME: Evidence for a common structure for a class of membrane channels. Eur J Biochem 213: 21-30, 1993.
65. Finbow ME, Pitts JD, Goldstein DJ, Schlegel R and Findlay JBC: The E5 oncoprotein target: a 16 kDa channel-forming protein with diverse functions. Mol Carcinogen 4: 441-444, 1991.
66. Schlegel R, Wade-Glass M, Rabson MS and Yang YC: The E5 transforming gene of bovine papillomavirus encodes a small hydrophobic polypeptide. Science 233: 464-467, 1986.
67. Leptak C, Ramon y Cajal S, Kulke R, Horwitz BH, Riese DJ, Dotto GP and DiMaio D: Tumourigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16. J Virol 65: 7078-7083, 1991.
68. Green M and Loewenstein PM: Demonstration that a chemically synthesised BPV1 oncoprotein and its C-terminal domain function to induce cellular DNA synthesis. Cell 51: 795-802, 1987.
69. Sparkowski J, Anders J and Schlegel R: E5 oncoprotein retained in the endoplasmic reticulum/cis Golgi still induces PDGF receptor auto-phosphrylation but does not transform cells. EMBO J 14: 3055-3063, 1995.
70. Sparkowski J, Mense M, Anders J and Schlegel R: E5 oncoprotein transmembrane mutants dissociate fibroblast transforming activity from 16-kilodalton protein binding and platelet-derived growth factor receptor binding and phosphorylation. J Virol 70: 2420-2430, 1996.
71. Faccini AM, Cairney M, Ashrafi GH, Finbow ME, Campo MS and Pitts JD: The bovine papillomavirus type 4 E8 protein binds to ductin (16 kDa) and causes loss of gap junction intercellular communication in primary fibroblasts. J Virol (In press).
72. Oelze I, Kartenbeck J, Crusius K and Alonso A: Human papillomavirus type 16 E5 protein affects cell-cell communication in an epithelial cell line. J Virol 69: 4489-4494, 1995.
73. Straight SW, Herman B and McCance DJ: The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J Virol 69: 3185-3192, 1995.
74. Leechanachai P, Banks L, Moreau F and Matlashewski G: The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene 7: 19-25, 1992.
75. Pim D, Collins M and Banks L: Human papillomavirus type 16 E5 gene stimulates the transforming activity of epidermal growth factor receptor. Oncogene 7: 27-32, 1992.
76. Schiller JT, Vass WC and Lowy DR: Identification of a second transforming region in bovine papillomavirus DNA. Proc Natl Acad Sci USA 81: 7880-7884, 1984.
77. Watanabe S, Kanda T and Yoskiike K: Human papillomavirus type 16 transformation of primary embryonic fibroblasts requires expression of open reading frames E6 and E7. J Virol 63: 965-969, 1989.
78. Lamberti C, Morrissey LC, Grossman SR and Androphy EJ: Transcriptional activation by the papillomavirus E6 zinc finger oncoprotein. EMBO J 9: 1907-1913, 1990.
79. Werness BA, Levine AJ and Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79, 1990.
80. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136, 1990.
81. Sedman SA, Barbosa MS, Vass WC, Hubbert NL, Haas JA, Lowy DR and Schiller JT: The full length E6 protein of human papillomavirus type 16 has transforming and transactivating activities and cooperates with E7 to immortalise keratinocytes in culture. J Virol 65: 4860-4866, 1991.
82. Desaintes C, Hallez S, van Alphen P and Burny A: Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type 16. J Virol 66: 325-333, 1992.
83. Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH and Laimins LA: Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53 mediated repression of transcription. EMBO J 11: 3045-3052, 1992.
84. Akutsu N, Shirasawa H, Asano T, Isono K and Simizu B: p53-dependent and -independent transactivation by the E6 protein of human papillomavirus type 16. J Gen Virol 77: 459-463, 1996.
85. Klingelhutz AJ, Foster SC and McDougall JK: Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380: 79-82, 1995.
86. Sherman L and Schlegel R: Serum- and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human papillomavirus type 16. J Virol 70: 3269-3279, 1996.
87. Hirono I, Ogino H, Fujimoto M, Yamada K, Yoshida Y, Ikagawa M and Okumura M: Induction of tumours in ACI rats given a diet containing ptaquiloside, a bracken carcinogen. J Natl Cancer Inst 79: 1143-1149, 1987.
88. Matsuoka A, Hirosawa A, Natori S, Iwasaki S, Sofuni T and Ishidate M: Mutagenicity of ptaquiloside, the carcinogen in bracken, and its related illudane-type sesquiterpenes. II. Chromosomal aberration tests with cultured mammalian cells. Mut Res 215: 179-185, 1989.
89. Matoba M, Saito E, Saito K, Koyama K, Natori S, Matsushima T and Takimoto M: Assay of ptaquiloside, the carcinogenic principle of bracken, Pteridium aquilinum, by mutagenicity testing in Salmonella typhimurium. Mutagenesis 2: 419-423, 1987.
90. El-Mofty M, Sadek I, Soliman A, Mohamed A and Sakre S: α-ecdysone, a new bracken fern factor responsible for neoplasm induction in the Egyptian toad (Bufo regularis). Nutr Cancer 9: 103-107, 1987.
91. Bjieldanes LF and Chang GW: Mutagenic activity of quercetin and related compounds. Science 197: 577-578, 1977.
92. Nakayasu M, Sakamoto H, Terada M, Nagao M and Sugimura T: Mutagenicity of quercetin in Chinese hamster lung cells in culture. Mut Res 174: 79-83, 1986.
93. Ishikawa M, Okada F, Hamada J, Hosokawa M and Kobayashi A: Changes in the tumourigenic and metastatic properties of tumour cells treated with quercetin or 5-azacytidine. Int J Cancer 39: 338-342, 1987.
94. Sakai A, Sasaki K, Mizusawa H and Ishidate M: Effects of quercetin, a plant flavonol, on the two stage transformation in vitro. Terat Care Mutagen 10: 333-340, 1990.
95. Ishidate M: Data book on Chromosomal Aberration Tests in vitro. Tokyo, LIC/Elsevier, 1988.
96. Van Wart-Hood JE, Linder ME and Burr JG: TPCK and quercetin act synergistically with vanadate to increase protein-tyrosine phosphorylation in avian cells. Oncogene 4: 1267-1271, 1989.
97. Matter WF, Brown RF and Vlahos CJ: The inhibition of phosphatidylinositol 3-kinase by quercetin and analogues. Biochem Biophys Comm 186: 624-631, 1992.
98. Campo MS, McCaffery RE, Doherty I, Kennedy IM and Jarrett WFH: The Harvey ras 1 gene is activated in papillomavirus associated carcinomas of the upper alimentary canal in cattle. Oncogene 5: 303-308, 1990.
99. Pennie WD and Campo MS: Synergism between bovine papillomavirus type 4 and the flavonoid quercetin in cell transformation in vitro. Virology 190: 861-865, 1992.
100. Cairney M and Campo MS: The synergism between bovine papillomavirus type 4 and quercetin is dependent on the timing of exposure. Carcinogenesis 16: 1997-2001, 1995.
101. Gaukroger J, Bradley A, O'Neil B, Smith K, Campo S and Jarrett W: Induction of virus producing tumours in athymic nude mice by bovine papillomavirus type 4. Vet Rec 125: 391-392, 1989.
102. Gaukroger JM, Bradley A, Chandrachud L, Jarrett WFH and Campo MS: Interaction between bovine papillomavirus type 4 and cocarcinogens in the production of malignant tumours. J Gen Virol 74: 2275-2280, 1993.
103. Smith KT, Campo MS, Bradley J, Gaukroger J and Jarret WFH: Cell transformation by bovine papillomavirus: cofactors and cellular responses. Cancer Cells 5: 267-274, 1987.
104. Quintanilla M, Brown K, Ramsden M and Balmain A: Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322: 78-80, 1986.
105. Wong DTW: Amplification of the c-erb-B1 oncogene in chemically induced oral carcinomas. Carcinogenesis 8: 1963-1965, 1987.
106. Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM and Jarrett WFH: Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 74: 945-953, 1993.
107. Christensen ND, Kreider JW, Kan NC and DiAngelo SL: The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralising epitopes. Virology 181: 572-579, 1991.
108. Lin YL, Borenstein LA, Selvakumar R, Ahmed R and Wettstein FO: Effective vaccination against papilloma development by immunisation with L1 or L2 structural proteins of cottontail rabbit papillomavirus. Virology 187: 612-619, 1992.
109. Campo MS and Jarrett WFH: Vaccination against cutaneous and mucosal papillomavirus in cattle. In: Vaccines Against Virally Induced Cancers. Ciba Foundation Symposium 187, pp61-77, 1994.
110. Chandrachud LM, Grindlay GJ, McGarvie GM, O'Neil BW, Wagner ER, Jarrett WFH and Campo MS: Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus type 4. Virology 211: 204-208, 1995.
111. Gaukroger JM, Chandrachud LM, O'Neil BW, Grindlay GJ, Knowles G and Campo MS: Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J Gen Virol 77: 1577-1583, 1996.
112. Zhou J, Sun XY, Stenzel DJ and Frazer IH: Expression of vaccinia recombinant HPV-16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185: 251-257, 1991.
113. Kirnbauer R, Booy F, Cheng N, Lowy DR and Shiller JT: Papillomavirus L1 major capsid protein self-assemble into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89: 12180-12184, 1992.
114. Haggensee ME, Olson NH, Baker TS and Galloway DA: Three dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol 68: 4503-4505, 1994.
115. Christensen ND, Hopfl R, DiAngelo SL, Cladel LM, Patrick SD, Welsh PA, Budgeon LR, Reed CA and Kreider JW: Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognised by neutralising monoclonal antibodies and induce high titers of neutralising antibodies. J Gen Virol 75: 2271-2276, 1994.
116. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR and Campo MS: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 218: 37-44, 1996.
117. Chandrachud LM, O'Neil BW, Jarrett WHF, Grindlay GJ, McGarvie GM and Campo MS: Humoral immune response to the E7 protein of bovine papillomavirus type 4 and identification of B-cell epitopes. Virology 200: 98-104, 1994.
118. Krchnak V, Vagner J, Suchankova A, Krcmar M, Ritterova L and Vonka V: Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA. J Gen Virol 59: 369-376, 1990.
119. Comerford SA, McCance DJ, Dougan G and Tite JP: Identification of T- and B-cell epitopes of the E7 protein of human papillomavirus type 16. J Virol 65: 4681-4690, 1991.
120. Tindle RW, Smith JA, Geysen HM, Selvey LA and Frazer IH: Identification of B-cell epitopes in human papillomavirus type 16 E7 open reading frame protein. J Gen Virol 71: 1347-1354, 1990.
121. Tindle R, Fernando GJP, Sterling J and Frazer IH: A 'public' T-helper epitope of the E7 transforming protein of human papillomavirus type 16 provides cognate help for several B-cell epitopes from cervical cancer associated human papillomavirus genotypes. Proc Natl Acad Sci USA 88: 5887-5891, 1991.
122. McGarvie GM, Grindlay GJ, Chandrachud LM, O'Neil BW, Jarrett WFH and and Campo MS: T cell responses to BPV-4 E7 during infection and mapping of T cell epitopes. Virology 206: 504-510, 1995.
123. Meneguzzi G, Cerni C, Kieny MP and Lathe R: Immunisation against human papillomavirus type 16 tumour cells with recombinant vaccinia viruses expressing E6 and E7. Virology 181: 62-69, 1991.
124. Chen L, Thomas EK, Hu SL, Hellstrom I and Hellstrom KE: Human papillomavirus type 16 nucleoprotein E7 is a tumour rejection antigen. Proc Natl Acad Sci USA 88: 110-114, 1991.
125. McLean CS, Sterling JS, Mowat J, Nash AA and Stanley MA: Delayed type hypersensitivity response to the human papillomavirus type 16 protein in a mouse model. J Gen Virol 74: 239-245, 1993.
126. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GWG, Westmoreland D, Evans AS, Adams AS, Stacey SN, Boursnell MEG, Rutherford E, Hickling JK and Inglis SC: A recombinant vaccinia virus encoding human papillomavirus type 16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347: 1523-1527, 1996.